|
Dr. Olivier LOGET, DVM ERT, CapEval Pharma CEO, has more than 26 years of experience in
pharma industry. He worked in toxicology departments since 1988 at
Sanofi-Synthelabo (Paris area), Hazleton/Ricerca (Lyon), CIT (Evreux), Roche
(Basel), Addex Pharma (Geneva), OriBase
Pharma (Montpellier) and CapEval Pharma (Geneva area). He is a Eurotox Registered
Toxicologist with great expertise in drug development from clinical candidate
selection through to entry into human. He joined Addex Pharma (Geneva) in 2006
as Head of Non-Clinical Drug Safety to participate in the IPO and to create,
develop and lead this department until 2010, when he created CapEval Pharma and
became CSO of OriBase Pharma. As OriBase
Pharma CSO (anticancer drug development), he brought a great expertise in
oncology drug development from candidate selection to clinical trials. At Roche
he was Head of Animal Experimentation and Toxicology Project Leader. He was
involved in several projects and Due Diligence opportunities.
|
|
He founded in
2010 CapEval Pharma, which he leads. He obtained his degree and doctorate in
Veterinary Medicine at the University of Nantes (1990). He is author or
co-author of more than 20 publications. He is co-founder of the European
Society of Laboratory Animal Veterinarians and board director of the
International Society of Ocular Toxicology. He is a lecturer teaching
preclinical R&D, toxicology in drug development and ocular examination in
several Research Institutes (INSERM, INRA), Universities and Veterinary
Schools.
|
| ;) Expert Partner ADME/PK
Sarah Resina, Ph.D., graduated from the Montpellier II University in
2007. After her doctorate in Biology and Health, she joined the DMPK department
of pharmaceutical company Sanofi-Aventis R&D and specialized in discovery
and preclinical pharmacokinetics. Then she worked as Project Manager at Medesis
Pharma, a biotechnology company dedicated to delivery nanotechnologies. She has
been in charge of new oiled formulations development on several indications such
as neuromuscular, metabolic and viral diseases. | |
|
|
|
| |
|
